Underlying the Mechanisms of Doxorubicin-Induced Acute Cardiotoxicity: Oxidative Stress and Cell Death
- PMID: 35002523
- PMCID: PMC8741835
- DOI: 10.7150/ijbs.65258
Underlying the Mechanisms of Doxorubicin-Induced Acute Cardiotoxicity: Oxidative Stress and Cell Death
Abstract
Cancer is a destructive disease that causes high levels of morbidity and mortality. Doxorubicin (DOX) is a highly efficient antineoplastic chemotherapeutic drug, but its use places survivors at risk for cardiotoxicity. Many studies have demonstrated that multiple factors are involved in DOX-induced acute cardiotoxicity. Among them, oxidative stress and cell death predominate. In this review, we provide a comprehensive overview of the mechanisms underlying the source and effect of free radicals and dependent cell death pathways induced by DOX. Hence, we attempt to explain the cellular mechanisms of oxidative stress and cell death that elicit acute cardiotoxicity and provide new insights for researchers to discover potential therapeutic strategies to prevent or reverse doxorubicin-induced cardiotoxicity.
Keywords: Doxorubicin; cardiotoxicity; cell death; oxidative stress.
© The author(s).
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures


Similar articles
-
Managing Doxorubicin Cardiotoxicity: Insights Into Molecular Mechanisms and Protective Strategies.J Biochem Mol Toxicol. 2025 Feb;39(2):e70155. doi: 10.1002/jbt.70155. J Biochem Mol Toxicol. 2025. PMID: 39887483 Review.
-
Dosing depending on SIRT3 activity attenuates doxorubicin-induced cardiotoxicity via elevated tolerance against mitochondrial dysfunction and oxidative stress.Biochem Biophys Res Commun. 2019 Sep 10;517(1):111-117. doi: 10.1016/j.bbrc.2019.07.029. Epub 2019 Jul 12. Biochem Biophys Res Commun. 2019. PMID: 31303273
-
Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management.Biomed Pharmacother. 2021 Jul;139:111708. doi: 10.1016/j.biopha.2021.111708. Epub 2021 May 13. Biomed Pharmacother. 2021. PMID: 34243633 Review.
-
Protective effects of dimethyl itaconate in mice acute cardiotoxicity induced by doxorubicin.Biochem Biophys Res Commun. 2019 Sep 24;517(3):538-544. doi: 10.1016/j.bbrc.2019.07.046. Epub 2019 Jul 31. Biochem Biophys Res Commun. 2019. PMID: 31376936
-
Toxicity of Doxorubicin (Dox) to different experimental organ systems.Life Sci. 2018 May 1;200:26-30. doi: 10.1016/j.lfs.2018.03.023. Epub 2018 Mar 10. Life Sci. 2018. PMID: 29534993 Review.
Cited by
-
Melatonin mitigates oxidative damage induced by anthracycline: a systematic-review and meta-analysis of murine models.Front Cardiovasc Med. 2023 Nov 23;10:1289384. doi: 10.3389/fcvm.2023.1289384. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 38075951 Free PMC article. Review.
-
Molecular Mechanisms and Therapeutic Targeting of Ferroptosis in Doxorubicin-Induced Cardiotoxicity.JACC Basic Transl Sci. 2024 Jan 3;9(6):811-826. doi: 10.1016/j.jacbts.2023.10.009. eCollection 2024 Jun. JACC Basic Transl Sci. 2024. PMID: 39070280 Free PMC article. Review.
-
The role of inflammasomes in human diseases and their potential as therapeutic targets.Signal Transduct Target Ther. 2024 Jan 5;9(1):10. doi: 10.1038/s41392-023-01687-y. Signal Transduct Target Ther. 2024. PMID: 38177104 Free PMC article. Review.
-
Momordica charantia L.-derived exosome-like nanovesicles stabilize p62 expression to ameliorate doxorubicin cardiotoxicity.J Nanobiotechnology. 2024 Aug 2;22(1):464. doi: 10.1186/s12951-024-02705-z. J Nanobiotechnology. 2024. PMID: 39095755 Free PMC article.
-
Cardiotoxicity monitoring of pyrotinib in combination with nab-paclitaxel, doxorubicin, and cyclophosphamide in HER2-positive breast cancer: a single-armed clinical trial.Gland Surg. 2022 Apr;11(4):742-750. doi: 10.21037/gs-22-161. Gland Surg. 2022. PMID: 35531104 Free PMC article.
References
-
- Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends-An Update. Cancer Epidemiol Biomarkers Prev. 2016;25:16–27. - PubMed
-
- Shelburne N, Simonds NI, Adhikari B, Alley M, Desvigne-Nickens P, Dimond E. et al. Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity. Curr Oncol Rep. 2019;21:9. - PubMed
-
- Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–7. - PubMed
-
- Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302–14. - PubMed
-
- Tomita S, Ishida M, Nakatani T, Fukuhara S, Hisashi Y, Ohtsu Y. et al. Bone marrow is a source of regenerated cardiomyocytes in doxorubicin-induced cardiomyopathy and granulocyte colony-stimulating factor enhances migration of bone marrow cells and attenuates cardiotoxicity of doxorubicin under electron microscopy. J Heart Lung Transplant. 2004;23:577–84. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources